Axopirox

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Axopirox

Property Description
Active ingredient Ciclopirox (often Ciclopirox olamine)
Form Topical (Nail lacquer, cream, solution, shampoo)
Pharmacological class Broad-spectrum Antifungal Agent (Antimycotic)
General purpose Clearing superficial fungal pathogens
Origin Synthetic

What Type of Medicine is Axopirox?

Axopirox is a pharmaceutical preparation defined by its active component, Ciclopirox, and is classified as a broad-spectrum antifungal agent or antimycotic. This medication is a synthetic drug intended for topical administration that belongs to the unique chemical group of hydroxypyridone derivatives. This class is recognized for its activity against a wide range of dermatophytes, yeasts, and molds. As a single-active ingredient product, its fundamental role is to directly combat superficial fungal infections on the skin, nails, and scalp, establishing its identity as a key dermatological anti-infective.


Composition and Physical Forms

The active ingredient, Ciclopirox, is a compound developed in a laboratory, underscoring its synthetic origin and chemical precision. Axopirox is distinguished in the market by being formulated into various dosage forms tailored for different application sites, including specialized nail lacquer (designed for hard, keratinous tissue), cream, topical solution, and shampoo. These forms utilize specialized bases—such as hydroalcoholic solvents for improved penetration or emollient matrices for general skin application—to maximize the contact time and efficacy of the active ingredient at the site of the infection.


General Therapeutic Purpose

The general purpose of this medicine is to address the source of external fungal issues by both stopping the pathogen's spread and eliminating the existing organisms. The dual functionality of Ciclopirox, characterized by both fungistatic (inhibiting growth) and fungicidal (killing fungi) actions, allows it to clear the infectious agent efficiently. Ciclopirox targets the fungal cell's ability to utilize essential nutrients and generate energy. This mechanism ensures the medicine works to actively eliminate the fungal threat. This comprehensive approach is key to restoring the appearance and health of the affected external tissue, serving as the foundational benefit of the Axopirox preparation. A typical scenario involves the preparation being used on the skin or nails when a fungal pathogen is confirmed to be present.

What side effects are possible with Axopirox?

Possible Side Effects and Safety Information

The safety profile of Axopirox (Ciclopirox topical) is defined by official regulatory documents, focusing primarily on localized reactions at the application site due to minimal systemic absorption.

Officially Documented Adverse Reactions

Adverse reactions are classified by frequency according to standardized regulatory terminology. Most reported events involve the Skin and Subcutaneous Tissue Disorders system organ class.

Frequency Classification Examples of Adverse Reactions
Common (Frequent) Burning sensation, erythema (redness), pruritus (itching), and transient exacerbation of local signs.
Uncommon (Infrequent) Hypersensitivity reactions (allergic reactions), vesicles at the application site.
Frequency Undetermined Contact dermatitis, hair discoloration, and alopecia (hair loss, specific to shampoo form).

Serious Safety Considerations

The most significant safety concern officially documented is Hypersensitivity (allergic reaction) to Ciclopirox or any component of the formulation. A known history of such hypersensitivity constitutes a formal contraindication and must be avoided. The product is also restricted and not for ophthalmic use (use in the eyes).

Population-Specific Safety Statements

Official labeling includes specific statements regarding data limitations for certain populations. The safety and effectiveness of the medication have not been established in pediatric patients below the age of 10 years. Furthermore, official regulatory documents note a lack of adequate, well-controlled studies regarding its use during pregnancy and lactation.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose manifestations for Axopirox are largely confined to the application site due to the minimal systemic absorption of Ciclopirox when applied topically. No specific systemic clinical signs, such as cardiovascular or neurological complications, are formally documented in regulatory prescribing information for topical overuse.

Documented Manifestations

Excessive topical application may result in signs of local chemical irritation or sensitization. The officially documented manifestations include erythema (redness), burning, pruritus (itching), swelling, or oozing at the site of use. The required action for these signs is the discontinuation of the product and the institution of supportive care.

Emergency Action and Risk

Accidental ingestion of the topical formulation represents the primary documented overdose risk. Immediate medical attention is mandated in the event of confirmed or suspected accidental swallowing. Regulatory labeling requires the product to be kept out of the reach of children to prevent this exposure risk.

Overdose Management

Management of overdose is restricted to symptomatic and supportive treatment. No specific antidote for Ciclopirox is known or documented in the regulatory labeling. Hospital monitoring may be required following significant ingestion to manage any potential systemic effects or complications that arise.

Therapeutic Uses of Axopirox

The primary role of Axopirox is to provide targeted symptomatic support across key domains of discomfort and functional limitation, especially where symptoms are intense or persistent. Axopirox is relevant in therapeutic areas that require additional symptomatic support for inflammatory conditions.

Axopirox is commonly used to help with symptomatic relief across three primary areas: symptoms related to inflammatory or irritative states, persistent discomfort, and impaired functional mobility.

Supportive Symptom Management

Axopirox is applied in clinical settings that involve acute or unstable symptom patterns. It helps address symptom clusters that may become intense or disruptive, such as swelling and stiffness. This supportive approach contributes to improved comfort during symptomatic periods. The medication provides supportive relief when symptoms interfere with routine activities, offering symptomatic relief that may assist patients to cope more steadily with symptom fluctuations.


Quick Fact: Use in Symptom Management Axopirox is commonly used to help with symptoms related to inflammatory or irritative states and functional strain.


Regulatory References

  1. European Medicines Agency overview of MabThera

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Axopirox (Ciclopirox) — Official Regulatory Information

The eligibility for Axopirox is determined strictly by regulatory constraints, primarily concerning hypersensitivity, age, and site of application. Use is allowed for adults and older adults, but is prohibited for certain populations and under specific circumstances.


Populations for whom use is contraindicated:

  • Individuals with a known history of hypersensitivity (allergy) to Ciclopirox or any inactive component of the specific product formulation.

Eligibility-Related Restrictions:

  • The product is strictly for external dermatologic use and is not for ophthalmic use (use in the eyes).
  • It must not be administered orally or intravaginally.

Age-Related Eligibility Rule Status as Defined in Official Labeling
Pediatric patients < 10 years (Cream/Suspension) Safety and effectiveness not established
Pediatric patients < 12/16 years (Nail Lacquer/Shampoo) Safety and effectiveness not established

Pregnancy and Lactation Eligibility Status:

  • Pregnancy (Category B): Use is permitted only if the potential benefit justifies the potential risk to the fetus, as adequate human studies are lacking.
  • Nursing Mothers: Caution should be exercised because it is not known whether the drug is excreted in human milk.

Official regulatory documents define eligibility by establishing absolute contraindications for allergic individuals and prohibiting non-topical use. Eligibility is further limited for children below specific age thresholds due to insufficient data, while use in pregnant and nursing women is restricted to conditional caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Axopirox (Ciclopirox topical) is characterized by a minimal risk of systemic drug-drug interactions. Due to the drug's topical route of administration and minimal systemic absorption, no clinically significant interactions involving major metabolic enzymes (such as CYP450) or drug transporters are documented in authoritative regulatory sources.


Official Interaction Restrictions

Category Regulatory Statement
Systemic Interactions No known clinically relevant pharmacokinetic interactions documented.
Timing-based Rule The treated nail area must be separated from exposure to water or bathing for a minimum of 8 hours after the application of the nail lacquer formulation.
Physical Interference Co-administration with cosmetic nail products (e.g., nail polish or artificial nails) is explicitly prohibited during the treatment period.
Concomitant Treatments Concomitant use with Systemic Antifungal Agents for onychomycosis is formally not recommended in official labeling, stemming from the lack of data to rule out potential interference with their efficacy.
Food or Alcohol No known interactions with food, alcohol, or herbal products are documented in regulatory prescribing information.

This structure ensures clear, mandated constraints are followed, defining the product's interaction structure based on the need to preserve local efficacy rather than concerns over systemic drug exposure.

Mechanism of Action

Targeting Fungal Respiration and Energy Collapse

The primary mechanism involves chelation, where Ciclopirox binds tightly to polyvalent cations (like ferric iron, Fe^3+) inside the fungal cell. By sequestering these essential cofactors, the drug effectively disables key metal-dependent enzymes in the Mitochondrial Electron Transport Chain. This action rapidly halts the fungal cell's ability to generate ATP (energy), initiating metabolic collapse and functional impairment.


Inducing Oxidative Stress for Pathogen Self-Toxicity

Beyond energy deprivation, Ciclopirox's action promotes a toxic environment by inhibiting fungal peroxide detoxification enzymes (Catalase and Peroxidase). The failure of these defense systems causes lethal levels of Reactive Oxygen Species (ROS) to accumulate, resulting in irreversible damage to the fungal cell's internal structures. This dual strategy results in both the inhibition of growth (fungistatic action) and the cellular death of the pathogen (fungicidal action).


️ Secondary Modulation of Local Tissue Inflammation

Ciclopirox also modulates the host tissue through the inhibition of Cyclooxygenase ( COX) and 5-Lipoxygenase ( 5-LOX) enzymes. This mechanism limits the local production of inflammatory mediators, such as Prostaglandins and Leukotrienes, which functionally reduces the local synthesis of inflammatory mediators and related tissue hyper-responsiveness.

Dosage and Administration Information

How to Use Axopirox

Axopirox (Ciclopirox) is strictly for topical administration to the skin, nails, or scalp. The official use of this medicine is defined by the specific dosage form required for the site of infection and the corresponding application regimen.


Administration Scope and Dosing

Application Site Approved Form/Strength Dosing Frequency
Nail (Onychomycosis) 8% Nail Lacquer Solution Once daily (preferably at bedtime)
Skin (Dermatophytoses) 0.77% / 1% Cream, Gel, or Lotion Twice daily (morning and evening)
Scalp (Seborrheic Dermatitis) 1% Shampoo Solution Twice weekly (minimum 3 days apart)

Use Duration and Procedural Requirements

Treatment duration varies significantly based on the application site. For most cutaneous fungal infections (tinea, candidiasis), the typical course is four weeks. However, the treatment duration for onychomycosis using the 8% Nail Lacquer may extend for up to 48 weeks.

The lacquer regimen requires specific preparation: the old coat must be removed weekly using alcohol, and the regimen is intended to be used in conjunction with monthly professional removal (debridement) of any unattached infected nail tissue. For topical skin applications, the medication is directed to be gently massaged into the affected area and the surrounding skin. Officially, the safety and efficacy of most formulations have not been established for use in young pediatric patients (often under 10 or 16), depending on the specific product type.

Recent Clinical Evidence

Axopirox, which contains the active ingredient Ciclopirox, has been studied for several common fungal and inflammatory conditions. The available research includes large-scale randomized controlled trials (RCTs) and systematic reviews. The summary below describes the types of research conducted and the aspects of the evidence that are still uncertain.


Evidence for Fungal Nail Infection (Onychomycosis) Research

Pivotal research for the nail lacquer formulation was evaluated in long-term randomized controlled trials over approximately 48 to 52 weeks. These studies primarily included immunocompetent adults with mild to moderate disease. Research examined primary measurements like mycological cure (laboratory assessment of fungal presence) and clinical cure (visual assessment of the nail). The results apply only to the populations studied, and limited information for long-term outcomes is available regarding the prevention of recurrence after treatment stops.


Evidence for Superficial Skin Fungal Infections

Research for the cream and solution forms was studied for short-term, vehicle-controlled clinical trials focusing on conditions like athlete's foot and ringworm. These studies were relevant in evidence describing how symptoms are measured during short-term patterns. Researchers examined outcomes linked to inflammatory states, including mycological clearance and the measured change in clinical signs. While core evidence is extensive in adults, comparative evidence is lacking against the full range of other topical alternatives, and data for certain groups remain insufficient.


Evidence for Seborrheic Dermatitis Studies

The active ingredient, Ciclopirox, in formulations such as shampoo or cream was studied for seborrheic dermatitis through medium-term, randomized, controlled trials. Studies monitored outcomes related to physical discomfort, tracking the reduction in symptoms like flaking and redness. Evidence is limited for patients presenting with severe disease, and long-term effects are not fully established regarding the optimal maintenance schedule to track the condition over many months.

Key Studies & References

  1. CICLOPIROX OLAMINE cream (Monograph/Package Insert Summary)

Frequently Asked Questions (FAQ)

Common questions about Axopirox (FAQ)

Q: How quickly can I expect to see results from using Axopirox?

A: According to official product information for topical skin infections, patients often begin to see clinical improvement, such as relief from associated itching and other symptoms, within the first week of starting treatment. For the best outcome, it is important to continue the treatment course for the full prescribed duration, as clearing the underlying infection takes longer.

Q: Is a slight stinging sensation normal when I first apply Axopirox?

A: Yes, regulatory documents indicate that a transient burning or stinging sensation can be experienced by some patients, especially when using certain formulations like the gel for scalp conditions. If this sensation is severe, persistent, or causes significant discomfort, it is recommended to seek guidance from a healthcare professional.

Q: Can Axopirox cause skin redness or irritation?

A: Official safety data lists several localized skin reactions as common adverse effects. These commonly include erythema (redness), itching (pruritus), burning, and localized irritation at the application site. These are typically temporary reactions that occur near the site of application.

Q: Can I use moisturizing lotions or cosmetics on the same area as Axopirox?

A: Official labeling explicitly prohibits using cosmetic nail products, such as nail polish or artificial nails, during treatment with the Axopirox nail lacquer. While general skin moisturizers or cosmetics are not specifically addressed in the regulatory interaction profile for skin use, it is a common practice to allow the medication to absorb fully before applying other topical products.

Q: Can children use Axopirox?

A: Regulatory information states that the safety and effectiveness of Axopirox are not established for pediatric patients below certain age thresholds, which vary by product form (e.g., under 10 or 16 years old). Use in children above these thresholds requires the guidance of a healthcare provider to determine appropriateness.

Q: Can women who are planning to become pregnant use Axopirox?

A: The official product information addresses use during pregnancy but does not contain specific regulatory guidance for the pre-conception or planning phase. Individuals who are planning to become pregnant should consult with a healthcare professional regarding the medication's use.

Q: Does applying more Axopirox than recommended make it work faster?

A: Official regulatory guidance instructs patients to use the medicine strictly as directed by the prescribed schedule and amount. Using more than the recommended quantity or frequency is not supported by official guidance as a way to enhance or speed up effectiveness and could potentially increase the risk of local side effects.

Q: What happens if the treated area gets wet after application?

A: The official label specifies that treated nails should not be exposed to water or bathing for at least eight hours after applying the nail lacquer formulation. No such specific time restriction regarding water exposure is provided for the cream or solution forms in the official regulatory documents.

Q: Can I use Axopirox at the same time as another topical steroid?

A: The regulatory label indicates that because the drug is minimally absorbed into the bloodstream, it has no known clinically significant systemic drug-drug interactions. However, the label does not provide specific studies or guidance regarding the simultaneous application of Axopirox with topical steroid creams or ointments.

Q: Does Axopirox contain any parabens or common allergens?

A: Regulatory documents require that all ingredients, including inactive components, be listed on the product label. An allergy or known hypersensitivity to any component of the specific formulation is a formal contraindication. You can refer to the official prescribing information or package leaflet to verify the full list of ingredients, including specific excipients.

Q: Does the efficacy of Axopirox depend on the condition's severity?

A: The clinical studies supporting the use of Axopirox were primarily conducted on adults diagnosed with mild to moderate disease. Official research summaries state that evidence may be limited regarding its effectiveness for patients presenting with severe forms of the condition.

Q: Does Axopirox completely cure the condition or just manage symptoms?

A: Axopirox is classified with both fungistatic (inhibits fungal growth) and fungicidal (kills fungi) actions. Clinical trials measure the drug's success by documenting 'mycological cure,' which refers to the clearance of the fungal pathogen, indicating the treatment is intended to eliminate the source of the infection.

Q: What's the difference between Axopirox cream and the lotion/solution version?

A: The difference primarily lies in their official use and application method. Regulatory documents indicate that the various dosage forms, such as the cream, solution, and lacquer, are approved for treating different parts of the body (e.g., skin, scalp, or nails) and are formulated with different bases to facilitate the drug's delivery.

Q: Is it safe to use Axopirox while taking vitamin supplements?

A: Official regulatory prescribing information does not document any known interactions between Axopirox and food, alcohol, herbal products, or common vitamin supplements. This is due to the drug's topical route of administration and minimal systemic absorption.

Q: If I miss a dose of Axopirox, what should I do?

A: Regulatory guidance suggests applying the missed dose as soon as you remember. However, if it is almost time for your next scheduled dose, the advice is to skip the missed dose and return to your regular application schedule.

Q: Is there a generic version of Axopirox available?

A: Yes, the active ingredient in Axopirox, Ciclopirox, is available in multiple generic topical formulations. These can often be verified through government drug product databases.

Q: Can Axopirox lose its effectiveness over time if used for a long period?

A: Official regulatory information does not specifically warn against a loss of effectiveness during prolonged, correct use, such as the long-term application required for nail treatment. However, if a patient does not show clinical improvement after a defined course of treatment, the diagnosis should be reassessed by a healthcare provider.

Q: Is it normal for the treated area to look slightly worse before it gets better with Axopirox?

A: Official safety documents list a 'transient exacerbation of local signs' as a common adverse reaction. This suggests that a temporary, mild worsening of symptoms at the application site can occasionally occur during the initial phase of treatment.

Q: Is Axopirox commonly used in dermatology practices?

A: Axopirox is officially indicated for treating common dermatological conditions, including various forms of ringworm (dermatophytoses) and seborrheic dermatitis. This confirms its role as an established and indicated treatment option within the field of dermatology.

Q: How should I clean the area before applying Axopirox?

A: Official patient instructions generally recommend that for the cream and lotion forms, the product should be applied and gently massaged into the affected and surrounding skin areas, often immediately after cleaning or washing the area to be treated.

Q: Can the heat or humidity where I live affect Axopirox?

A: Yes, official storage instructions require that Axopirox be kept at a controlled room temperature (typically 20^circC to 25^circC). It must be protected from excessive heat and moisture to ensure the medication remains stable and effective.

Q: Is there a limit to how many times a day Axopirox can be applied safely?

A: Official regulatory guidance recommends that the approved dosing frequency should not be exceeded. The standard dosing for skin infections is typically twice daily, and the product information limits use to the prescribed regimen.

Q: Do many people experience dryness when using Axopirox?

A: Dry skin is listed as a commonly reported adverse reaction to Axopirox in official safety documentation. Consulting a healthcare provider is recommended if skin dryness continues or becomes bothersome.

How should Axopirox be stored and disposed of?

How to Store and Dispose of Axopirox (Ciclopirox Topical)

The storage and disposal of Axopirox are governed by official regulatory requirements to ensure product stability and safety.

Storage Requirements

Storage Condition Requirement
Temperature Store at Controlled Room Temperature, 20 to 25 C (68 to 77 F).
Container & Protection Keep in the container it came in and keep it tightly closed; protect from freezing, excessive heat, moisture, and direct light.
Safety It is mandatory to keep Axopirox out of the reach of children.
Special Handling Keep the topical solutions and lacquers away from heat and open flame due to flammability.

Disposal

Unused or expired Axopirox must not be kept. Disposal should be done through an authorized drug take-back program as the preferred method, or according to specific local regulations for household waste if no program is available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Axopirox found in:

A-Z Index: